18F-FDG PET/CT in primary brain lymphoma

Area of Science:

• Nuclear Medicine
• Oncology
• Neurology

Background:

• The diagnostic role of 18F-FDG PET/CT in primary brain lymphoma remains under investigation.
• Brain lymphomas typically exhibit elevated 18F-FDG uptake, often exceeding that of other brain tumors and inflammatory conditions.
• The specific metabolic characteristics of brain lymphoma require further elucidation.

Purpose of the Study:

• To investigate the distinct metabolic behavior of primary brain lymphoma using 18F-FDG PET/CT.
• To correlate metabolic activity with epidemiological and morphological features of brain lymphoma.

Main Methods:

• Retrospective analysis of 46 patients with histologically confirmed brain lymphoma who underwent whole-body 18F-FDG PET/CT for initial staging.
• Visual and semi-quantitative PET image analysis, including SUVmax, lesion-to-liver SUVmax ratio, lesion-to-blood pool SUVmax ratio, and tumor-to-normal brain uptake ratio (T/N ratio).
• Comparison of PET findings with epidemiological (age, sex, HIV status) and morphological (tumor size, MRI appearance) data.

Main Results:

• 83% of patients (38/46) demonstrated positive 18F-FDG uptake in their brain lesions (average SUVmax 15.6 ± 9.2).
• 18F-FDG avidity was significantly associated with morphological appearance and tumor size, but not with other epidemiological factors.
• 18F-FDG PET/CT identified extracranial disease in 2 cases (4%) where bone marrow biopsies and CT were negative.

Conclusions:

• Primary brain lymphomas are predominantly 18F-FDG avid (83%), exhibiting high uptake.
• 18F-FDG avidity correlates with tumor size and morphological characteristics.
• 18F-FDG PET/CT is valuable for staging, detecting extracranial disease, and understanding the metabolic profile of brain lymphomas.